Wockhardt Limited (NSE:WOCKPHARMA)
India
· Delayed Price · Currency is INR 1,316.55
-68.60 (-4.95%)
Feb 21, 2025, 3:29 PM IST
Wockhardt Revenue
Wockhardt had revenue of 7.21B INR in the quarter ending December 31, 2024, with 2.85% growth. This brings the company's revenue in the last twelve months to 30.01B, up 8.11% year-over-year. In the fiscal year ending March 31, 2024, Wockhardt had annual revenue of 28.30B with 6.51% growth.
Revenue (ttm)
30.01B
Revenue Growth
+8.11%
P/S Ratio
6.72
Revenue / Employee
12.58M
Employees
2,386
Market Cap
213.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | 28.44B | -7.22B | -20.24% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Wockhardt News
- 16 days ago - Wockhardt reports Q3 Results: Revenue up 3% to Rs 721 crore, Net profit at Rs 20 crore vs loss of Rs 86 crore YoY - Business Upturn
- 23 days ago - Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success - Business Upturn
- 23 days ago - Wockhardt’s Zaynich achieves 96.8% clinical cure rate, sets new benchmark in Phase III global study - Business Upturn
- 5 weeks ago - Wockhardt’s Zaynich achieves 97% efficacy in treating resistant infections - Business Upturn
- 7 weeks ago - Wockhardt shares surge nearly 5% after CDSCO approval for revolutionary antibiotic Miqnaf - Business Upturn
- 7 weeks ago - Stocks in Focus Today on January 4, 2025: Wockhardt, NHPC, RITES, IRFC, Hind Zinc and more - Business Upturn
- 7 weeks ago - Wockhardt launches new-generation oral antibiotic Miqnaf for community-acquired bacterial pneumonia (CABP) - Business Upturn
- 2 months ago - Wockhardt shares surge over 4% on successful Zaynich treatment for drug-resistant infections - Business Upturn